ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.

计划入组 11 人 · 首次发布于 2007 年 2 月 27 日

Panobinostat Maintenance After HSCT fo High-risk AML and MDS

计划入组 52 人 · 首次发布于 2020 年 3 月 30 日

Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

计划入组 340 人 · 首次发布于 2003 年 1 月 27 日

JONG HOON LEE

Australia

LEE JONG HOON

United States

Active Biotech's Tasquinimod Trial for Myelofibrosis Receives European Approval

First Patient Enrolled in Phase Ib/II Trial of Tasquinimod for Treatment-Resistant Myelofibrosis

Measurable Residual Disease Validated as Strong Predictor of Survival in AML Patients